PON1 Cardiovascular Protection and Antioxidants | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-26 · 5 min read

The Enzyme That Protects HDL's Protective Function

High-density lipoprotein is conventionally framed as 'good cholesterol', a simple, unidimensional assessment of a molecularly complex particle. HDL's cardioprotective function depends not simply on its abundance but on its biological cargo. One of the most important proteins carried on HDL particles is paraoxonase-1 (PON1), an enzyme that hydrolyzes oxidized phospholipids from LDL particles before they are taken up by arterial macrophages and converted into foam cells, the cellular building blocks of atherosclerotic plaque.

When PON1 function is reduced, oxidized LDL accumulates in the arterial wall unchecked. Macrophages take up the oxidized particles, become cholesterol-laden foam cells, and die within the arterial intima, releasing their contents to fuel the chronic inflammatory cascade of progressive atherosclerosis. The lipid panel shows 'normal' numbers. The arterial wall tells a different biological story.

The Q192R and L55M Variants

The Q192R polymorphism, rs662, substitutes arginine for glutamine at position 192 of the PON1 protein. The R allele produces a enzyme with higher activity against some substrates (paraoxon) but lower activity against others (oxidized phosphatidylcholine), creating a substrate-specific catalytic profile that is particularly disadvantageous for oxidized LDL hydrolysis.

The L55M variant, rs854560, reduces PON1 protein stability and serum enzyme levels by approximately 35 percent in MM homozygotes. The compound genotype, low-stability enzyme (MM) operating with altered substrate preference (RR), produces a PON1 system that is both quantitatively and qualitatively deficient at performing its primary cardiovascular protective function.

A 2024 systematic review in Atherosclerosis confirmed that compound PON1 low-activity genotypes confer a significantly elevated risk of coronary artery disease, carotid intima-media thickness progression, and myocardial infarction independent of LDL cholesterol levels, smoking status, and blood pressure.

Beyond the Lipid Panel

PON1 status represents precisely the kind of cardiovascular risk information that standard clinical biochemistry cannot capture. A patient with LDL of 110 mg/dL who carries PON1 low-activity variants has meaningfully higher oxidative atherogenic burden than a patient with the same LDL and high PON1 function, and requires correspondingly different preventive strategies.

The GENEFLAMMATION protocol maps PON1 Q192R and L55M alongside the full antioxidant pathway and inflammatory regulatory profile to build a cardiovascular oxidative risk picture that informs targeted antioxidant supplementation, polyphenol dosing calibrated to PON1 induction potential, and dietary fat composition strategies.